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Abstract: Obesity, metabolic syndrome and diabetes are conditions with increasing prevalence 
around the world. Cardiovascular risk in diabetics is often so high as to overlap with event 
rates observed in those with established coronary disease and this has lead to diabetes being 
classiﬁ  ed as a coronary risk equivalent. However, despite the elevated risk of cardiovascular 
events associated with diabetes and the metabolic syndrome, these patients often have normal 
low density lipoprotein (LDL) cholesterol despite frequent increases in apolipoprotein B, tri-
glycerides and nonhigh density lipoprotein (HDL) cholesterol. In contrast to LDL cholesterol, 
non-HDL cholesterol represents cardiovascular risk across all patient populations but is cur-
rently only recommended as a secondary target of therapy by the ATP III report for patients 
with hypertriglyceridemia. This article provides an overview of the studies that shown non-HDL 
cholesterol to be superior to LDL cholesterol in predicting cardiovascular events and presents 
the case for non-HDL cholesterol being the more appropriate primary target of therapy in the 
context of the obesity pandemic. Adopting non-HDL cholesterol as the primary therapeutic 
target for all patients will conceivably lead to an appropriate intensiﬁ  cation of therapy for high 
risk patients with low LDL cholesterol.
Keywords: obesity, coronary artery disease, non-HDL cholesterol, LDL cholesterol, metabolic 
syndrome, diabetes
LDL cholesterol: The current target of therapy
Epidemiologic data from populations with and without coronary artery disease (CAD) 
have highlighted the importance of reducing low density lipoprotein cholesterol 
(LDL-C) in preventing both new-onset CAD and recurrent ischemic events (Stamler 
et al 1986, 1984b, 1984a; Rossouw et al 1990; Wong et al 1991; Wilson et al 1998). 
Indeed, there is a log-linear relationship between LDL-C and CAD risk, and this 
relationship holds true at low LDL-C levels (Grundy et al 2004). Not surprisingly, 
LDL-C was identiﬁ  ed by the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel (ATP) reports as being the primary focus of cholesterol-reducing 
therapy and successive NCEP ATP reports have recommended successively lower 
LDL-C goals for high risk patients (ATP III 2002). However, the ATP-III report 
acknowledges that when serum triglycerides (TG) are  200 mg/dl, increased remnant 
atherogenic lipoproteins greatly heighten risk predicted by LDL-C and this is associated 
with a substantially elevated very low density lipoprotein cholesterol (VLDL-C) (ATP 
III 2002). VLDL-C is not accounted for by the calculation of LDL-C in standard lipid 
panels. When serum TG is  150 mg/dl, VLDL-C is usually  30 mg/dl and hence 
VLDL-C arguably makes a small contribution to the atherogenic cholesterol pool Vascular Health and Risk Management 2008:4(1) 144
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(1979). However, for patients with TG 200 mg/dl, non high 
density lipoprotein cholesterol (non-HDL-C) is identiﬁ  ed as a 
secondary target of therapy with the target being  30 mg/dl 
greater than the LDL-C target (ATP III 2002). Non-HDL-C 
is simply calculated from a standard lipid panel as total 
cholesterol (TC) minus HDL-C and accounts for LDL-C, 
VLDL-C, IDL-C, chylomicron remnants, and lipoprotein 
a. Non-HDL-C is highly correlated with apolipoprotein B 
(apoB) and therefore provides a more accurate measure of 
the cholesterol in atherogenic particles (ATP III 2002). While 
non-HDL-C is highly correlated with LDL-C (r = 0.94), at 
TG  150 mg/dl, non-HDL-C becomes displaced upwards 
and the correlation weakens (Abate et al 1993). Since hyper-
triglyceridemia affects 16% of the American population and 
37% of diabetics (Shepherd 2005), non-HDL-C may be a 
more appropriate primary target of therapy since LDL-C may 
be less reliable for risk prediction in a sizeable proportion of 
the population (Pischon et al 2005). Moreover, non-HDL-C 
may be a superior predictor of CAD events regardless of TG; 
a 5794 person cohort from the Framingham study showed 
non-HDL-C to be a superior predictor of CAD events com-
pared with LDL-C and also showed VLDL-C to predict 
CAD events after adjusting for LDL-C in patients with TG 
 200 mg/dl and in patients with TG  200 mg/dl (Liu et al 
2006). Further, VLDL-C correlated poorly (r = 0.08) with 
LDL-C and an advantage of a non-HDL-C target is that it 
incorporates both LDL-C and VLDL-C. The triglyceride-rich 
lipoproteins which are not accounted for by LDL-C measure-
ment have been associated with both increased angiographic 
progression of CAD and hard clinical end points (Phillips 
et al 1993; Mack et al 1996; Sacks et al 2000). Further, 
non-HDL-C is inversely correlated to HDL-C in adults and 
children (Gordon et al 1989, Srinivasan et al 2002). The 
need to change the primary target of therapy is arguably 
more pressing given the increasing prevalence of obesity, 
diabetes, the metabolic syndrome and hypertriglyceridemia; 
this paper proposes that non-HDL-C should be the primary 
target of therapy for all patients.
Diabetes, obesity, metabolic 
syndrome, atherogenic dyslipidemia 
and cardiovascular events
Recent data from the Framingham Offspring study have 
shown that the incidence of type 2 diabetes in the 1990s 
has doubled when compared to the 1970s, with most of 
the absolute increase in diabetes incidence occurring in the 
obese as determined by body mass index (BMI) of greater 
than 30 (Fox et al 2006). This ﬁ  nding is concordant with 
secular trends found in the San Antonio Heart Study from 
1987–1996 (Burke et al 1999). Data collected from the 
Framingham cohort over 5 decades has shown that the bur-
den of cardiovascular disease is increasingly attributable to 
diabetes mellitus (Fox et al 2007a). Some studies have shown 
diabetics without previous myocardial infarction to harbor the 
same risk of cardiovascular death and myocardial infarction 
as non-diabetic patients with previous myocardial infarction 
(Haffner et al 1998). However, this high risk of cardiovascu-
lar events in diabetics depends on co-existing cardiovascular 
risk factors as shown in the Strong Heart Study and the Mul-
tiple Risk Factor Intervention Trial (MRFIT) (Vaccaro et al 
1998; Howard et al 2006). Similarly, in an National Health 
and Nutrition Examination Survey (NHANES III) analysis, 
patients with diabetes but without the metabolic syndrome 
(only 14% of diabetics) did not have an increased risk of 
CAD (Alexander et al 2003). The diagnosis of the metabolic 
syndrome (criteria in Table 1) describes the clustering of 
central adiposity with impaired fasting glucose, elevated 
blood pressure, high TG, and low HDL-C (Grundy 2005; 
Zimmet et al 2005; Pladevall et al 2006) and, like diabetes, 
is associated with an increased risk of cardiovascular events 
(Bonora et al 2000; Lakka et al 2002; Malik et al 2004; Butler 
et al 2006; Nigam et al 2006). Individual components of the 
Table 1 ATP III and IDF Deﬁ  nitions of the metabolic syndrome (ATPIII 2002; Liberopoulos et al 2005).
IDF Criteria (ﬁ  rst criterion compulsory plus any additional 2) ATP III Criteria (3/5 required for diagnosis)
Waist circumference  94 cm in Europid males or   80 cm in Europid 
females (with ethnic-speciﬁ  c values for other groups)
Waist circumference  102 cm in males or   88 cm in females
Triglycerides  150 mg/dl or speciﬁ  c treatment for lipid abnormality Triglycerides  150 mg/dl
HDL cholesterol  40 mg/dl in a male or  50 mg/dl in a female or speciﬁ  c 
treatment for lipid abnormality
HDL cholesterol  40 mg/dl in a male or  50 mg/dl in a female
Blood pressure  130/85 or antihypertensive medications Blood pressure  130/85 or anti-hypertensive medications
Fasting glucose  100 mg/dl or previously diagnosed type 2 diabetes Fasting glucose  110 mg/dlVascular Health and Risk Management 2008:4(1) 145
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metabolic syndrome, like impaired fasting glucose have been 
shown to be independently associated with an increased risk 
of cardiovascular death (Barr et al 2007). This clustering of 
risk factors is ultimately driven by visceral adiposity which 
can be quantiﬁ  ed by waist circumference measurements or 
imaging studies which, with insulin resistance, drives the 
increased risk of cardiovascular events (Carr et al 2004; 
Grundy et al 2005; Zimmet et al 2005; Bonora 2006; Grundy 
2006). Since obesity, metabolic syndrome, and diabetes are 
common conditions, treating the ensuing increased risk of 
cardiovascular events is of great public health signiﬁ  cance.
NHANES data has shown roughly one third of American 
adults over the age of 20 to be obese, 9.3% of Americans 
to be diabetic with another 26% having impaired fasting 
glucose, and a nearly double prevalence of diabetes in 
minorities (Cowie et al 2006; Ogden et al 2006). The meta-
bolic syndrome is similarly prevalent and affects roughly a 
quarter of Americans above the age of 20 (Ford et al 2004) 
and 44% of Americans over the age of 50 (Alexander et al 
2003). The purpose of this paper is to discuss the alterations 
in lipid parameters that occur with obesity and to argue that 
non-HDL-C is a more appropriate target for lipid-lowering 
therapy than LDL-C given that, as societies, we are becom-
ing fatter and more diabetes-prone (Flegal et al 2002; Ford 
et al 2003). This is especially topical as absolute risk for 
cardiovascular events in primary prevention and second-
ary prevention increasingly overlap, largely driven by the 
increase in obesity, metabolic syndrome and diabetes in the 
primary prevention setting (Vaccaro et al 1998; Howard et al 
2000, 2006; ATP III 2002).
The lipid proﬁ  le of obesity
In an analysis of men enrolled in the NHANES II database, 
increasing BMI was associated with higher TC, TG, and 
non-HDL-C, but with lower HDL-C. In middle-aged and 
older men, LDL-C did not vary with BMI (Denke et al 
1993). Indeed, while excess body weight has been consis-
tently associated with increases in TG, VLDL-C, TC, and 
decreased HDL-C, the effects of body weight on LDL-C have 
been variable (Foster et al 1987; Jacobs et al 1988; Meilahn 
et al 1988; Denke et al 1994). Further, while TC and LDL-C 
generally correlate on a population level, this correlation 
weakens at higher body weights where VLDL-C makes a 
larger contribution to TC (Wolf and Grundy 1983a). Simi-
larly, obese children have higher TC and TG than non-obese 
children with no signiﬁ  cant difference in LDL-C (Friedland 
et al 2002). In a pediatric population, non-HDL-C correlated 
with BMI and with waist circumference while LDL-C did 
not (Srinivasan et al 2002). Such observations in children are 
highly relevant to preventative cardiologists since children 
with higher non-HDL-C are more likely as adults to have 
high non-HDL-C, to be obese adults, to have hypertriglyc-
eridemia, impaired fasting glucose, hyperinsulinemia, and 
low HDL-C while LDL-C levels in children are not similarly 
predictive (Srinivasan et al 2006). An analysis of adults in the 
NHANES III dataset corroborated these ﬁ  ndings in children 
and showed non-HDL-C to be a signiﬁ  cantly stronger cor-
relate with BMI than LDL-C (Gardner et al 2000). Similarly, 
the accumulation of visceral adipose tissue which drives 
the metabolic syndrome and diabetes is associated with the 
lipoprotein proﬁ  le of obesity which includes a normal LDL-C 
despite elevated cardiovascular risk (Yusuf et al 2005). Intra-
abdominal fat, quantiﬁ  ed with computed tomography scan-
ning, correlates with insulin resistance and patients with high 
amounts of intra-abdominal fat and greater degrees of insulin 
resistance have elevated TC, TG, ApoB, VLDL-C, and less 
HDL-C (Nieves et al 2003). Similarly, in the Framingham 
cohort, TC and TG were shown to correlate positively with 
visceral adipose tissue while HDL-C correlated negatively 
(Fox et al 2007b). Determination of LDL-C is not informative 
of these changes in lipid parameters that are concomitants of 
the accumulation of visceral fat.
The NHANES III data set suggests that at least 13 mil-
lion US adults with CAD or CAD risk equivalents have an 
LDL-C of  130 mg/dl while 5 million US adults have an 
LDL-C  100 mg/dl (Case et al 2003) and hence may not 
qualify for drug therapy based on current ATP III guidelines. 
Further, most patients who develop ischemic heart disease 
have LDL-C levels in the ‘normal’ range (Stamler et al 1993) 
and a cross-sectional analysis from the Framingham cohort 
showed that men with CAD have LDL-C that is no different 
from those without CAD (Schaefer et al 1994). Importantly, 
non-HDL-C was signiﬁ  cantly higher in CAD than in control 
subjects (Schaefer et al 1994) and hence the adoption of non-
HDL-C as a primary target of therapy may lead to appropriate 
intensiﬁ  cation of therapy. From a pathophysiologic perspec-
tive, non-HDL-C better reﬂ  ects the increased cardiovascular 
risk associated with high apoB levels and small LDL particle 
size which are hallmarks of obesity.
Cholesterol metabolism in obesity 
and insulin resistance
Lipoprotein kinetic studies show that the liver overproduces 
apoB and triglycerides in the VLDL fraction in obesity and 
the two drivers of this process are hypertriglyceridemia and 
insulin resistance (McNamara et al 1987; Barrett and Watts Vascular Health and Risk Management 2008:4(1) 146
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2003; Chan et al 2003). Further, obesity is associated with an 
increase in cholesterol synthesis and a decrease in intestinal 
absorption (Nestel et al 1969; Miettinen 1971; Kempen et al 
1988; Hoenig et al 2007) and these variables are responsive 
to weight loss (Miettinen 1971). In 2000, Miettinen sug-
gested that low cholesterol absorption is a component of the 
metabolic syndrome (Simonen et al 2000). Not surprisingly, 
the changes in cholesterol metabolism in type 2 diabetics are 
similar to those seen in obese individuals; namely a lowered 
cholesterol absorption efficiency, decreased absorption 
marker ratios (Briones et al 1986; Gylling and Miettinen 
1997; Simonen et al 2000, 2002) and increased levels of 
synthesis markers and cholesterol synthesis determined with 
sterol balance (Bennion and Grundy 1977; Gylling and Miet-
tinen 1997; Simonen et al 2002; Nathan et al 2005; Hoenig 
et al 2007). The signiﬁ  cance of these observations is that 
VLDL-C is an independent predictor of CAD events, after 
adjustment for LDL-C (Liu et al 2006). Conversely, weight 
loss has been shown to produce consistent reductions in 
VLDL-C, TG levels and increases in HDL-C with variable 
effects on LDL-C (Brownell and Stunkard 1981; Wolf and 
Grundy 1983b; Follick et al 1984; Wood et al 1988). Mea-
suring non-HDL-C includes the cholesterol in the VLDL 
fraction and therefore better capitulates this shift in pheno-
type to increased cholesterol synthesis with obesity whereas 
considering LDL-C alone is uninformative. Higher BMI is 
associated with increases in non-HDL-C, TC, VLDL-C, 
and apoB, reﬂ  ecting higher hepatic synthesis of VLDL and 
an increased number of atherogenic particles (Lamon-Fava 
et al 1996). In contrast to non-HDL-C, LDL-C often remains 
unchanged in obesity and insulin resistance.
Non-HDL-C correlates better than 
LDL-C with apoB
Patients with the metabolic syndrome have an increased con-
centration of apoB and TC despite no difference in LDL-C 
compared with individuals without the metabolic syndrome 
(Hulthe et al 2000). In this context, it is hardly surprising 
that apoB concentrations added to the predictive value of 
LDL-C in the Quebec Heart Study which was a prospective 
cohort followed for 13 years (St-Pierre et al 2006). Further, 
there was poor concordance between LDL-C and apoB 
values in this population, especially amongst the majority 
of the population in the middle quintiles of LDL-C. Non-
HLD-C was a superior correlate to ApoB than LDL-C and 
those with disproportionately elevated apoB were those with 
higher BMI, higher TG, lower HDL-C, and smaller LDL 
particles, ie, features of the metabolic syndrome (Sniderman 
et al 2003b). The superior correlation of non-HDL-C with 
apoB compared to LDL-C is also illustrated by data from the 
Atorvastatin Comparative Cholesterol Efﬁ  cacy and Safety 
Study (ACCESS) investigators. Non-HDL-C correlated 
better with apoB than LDL-C, especially in patients with 
CAD and non-HDL-C correlated with ApoB (r   0.90) 
across all TG strata while the correlation between LDL-C 
and apoB deteriorated as TG increased (r = 0.81 if TG   250 
mg/dl) and was poorer in those with CAD (r = 0.81) than in 
lower risk patients without CAD (r = 0.86) (Ballantyne et al 
2001). The measurement of apoB levels for cardiovascular 
risk prognostication has its supporters, especially in Canada 
(Genest et al 2003) and is the ‘gold standard’ for cardiovas-
cular risk management according to its proponents (Walldius 
et al 2001; Sniderman et al 2003a). ApoB assays have been 
standardized and several experts have championed the inclu-
sion of apoB measurement in treatment guidelines (Barter 
et al 2006). While non-HDL-C correlates well with apoB, its 
concordance has been relatively poorer (Barter et al 2006). 
However, the prognostic utility of non-HDL-C in predict-
ing the hard clinical endpoint (discussed below) is perhaps 
the primary consideration for the clinician. Moreover, on a 
worldwide basis, the standard lipid panel remains the main-
stay of lipid assessment and the adoption of non-HDL-C as 
the primary therapeutic target would not require clinician 
re-education to the same extent that adoption of apoB as a 
therapeutic target would. As such, to replace LDL-C as the 
primary therapeutic target with non-HDL-C instead of apoB 
may be based more on pragmatism than evidence per se.
Non-HDL-C correlates better 
than LDL-C with small dense LDL 
particles
As well as being associated with increased apoB, obesity and 
diabetes have been associated with a preponderance for small, 
dense LDL particles. Just as non-HDL-C is a better correlate 
of apoB than LDL-C, elevated non-HDL-C is associated with 
smaller LDL particle size while elevated LDL-C is not. Pro-
spective cohort data from the Quebec Cardiovascular Study 
show that an increased risk of cardiovascular events is asso-
ciated with a preferential accumulation of small dense LDL 
particles  255A (St-Pierre et al 2001, 2005). While LDL-C 
in patients who developed CAD was a mere 8% higher than 
those without disease, the increase in cholesterol carried in 
small LDL particles ( 255A) was 40% (St-Pierre et al 2001). 
As expected, individuals with a preferential accumulation of 
cholesterol in small dense LDL particles had higher BMI, 
elevated TG, lower HDL-C and higher insulin levels, which Vascular Health and Risk Management 2008:4(1) 147
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are all features of the metabolic syndrome (St-Pierre et al 
2005). Conversely, the preferential accumulation of choles-
terol in larger LDL particles ( 260A) was associated with 
a relatively reduced incidence of ischemic heart disease and 
fewer features of the metabolic syndrome (St-Pierre et al 
2005). Similarly, in the Framingham cohort, LDL-C was not 
signiﬁ  cantly different in men with and without the metabolic 
syndrome although those with the metabolic syndrome had 
a greater number of small LDL particles, a smaller average 
LDL size and greater apoB (Kathiresan et al 2006). While 
LDL particle size bears no correlation to LDL-C, patients 
with smaller LDL particles had higher TC, non-HDL-C 
and TG with lower HDL-C than those with larger LDL 
particle size (Hulthe et al 2000). Similarly, data from the 
EPIC-Norfolk Prospective Population Study has shown 
non-HDL-C to correlate inversely with LDL particle size 
(p   0.01) while there was no correlation between LDL-C 
and LDL particle size (p = 0.6) (El Harchaoui et al 2007). 
Given that determination of LDL size is not part of routine 
patient care and LDL-C levels are usually normal or mildly 
elevated in those with diabetes, an alternative to LDL-C to 
quantify risk appears to be warranted.
Non-HDL-C is superior to LDL-C 
in cardiovascular risk prediction
While non-HDL-C has been correlated to cardiovascular 
events in epidemiologic studies (Keys et al 1984; Pocock 
et al 1986; Menotti et al 1992; Bos et al 2003), the purpose 
of this section is to describe studies that have compared 
the predictive value of non-HDL-C with LDL-C. Where 
data is available, the predictive value of non-HDL-C is also 
compared with apoB. While non-HDL-C levels have been 
associated with fatty streaks, vascular stenoses, angiographic 
progression of CAD, and carotid IMT (Bittner 2004), the 
linking of non-HDL-C to the hard clinical endpoint is of 
greater prognostic and therapeutic value and is crucial to 
effecting guideline change. Hence, this section only deals 
with studies that have reported hard clinical end points. 
These are summarized in Table 2 and selected studies are 
discussed herein. To the author’s knowledge, this is the most 
comprehensive assimilation of such studies.
In a 5794 patient cohort from Framingham who were 
initially free from CAD, VLDL-C predicted CAD events 
after adjustment for LDL-C (Liu et al 2006). Further, within 
each LDL-C category ( 130 mg/dl, 130–159 mg/dl,  160 
mg/dl), non-HDL-C ( 160 mg/dl, 160–189 mg/dl,  190 
mg/dl) was additionally predictive of CAD event rates but 
within each non-HDL-C category, LDL-C was not predictive 
of event rates (Liu et al 2006). As expected, LDL-C predicted 
CAD events in patients with TG  200 mg/dl (RR 1.009 per 
mg/dl increase, p   0.01) as did non-HDL-C (RR1.008 per 
mg/dl increase, p   0.01). However, LDL-C lost predictive 
value in patients with TG   200 mg/dl while non-HDL-C 
remained predictive (RR1.006 per mg/dl increase, p   0.01) 
(Liu et al 2006). Hence, non-HDL-C is a better predictor of 
CAD events and can be utilized ‘across the board’ regardless 
of TG. Interestingly, a study of diabetic women enrolled in 
the Nurses’ Health study showed the predictive value of non-
HDL-C to interact with TG. For the population as a whole 
(n = 921), the multivariate hazard ratio for a fourth:ﬁ  rst quar-
tile non-HDL-C value was 1.97 (p = 0.016) but in those with 
a TG   200 mg/dl, the hazard ratio for a fourth:ﬁ  rst quartile 
non-HDL-C was 3.80 (p = 0.046) with a p for interaction of 
0.045 (Schulze et al 2004). The conﬁ  dence intervals for the 
hazard ratios were however wide and overlapping. Hence 
while available studies have suggested that non-HDL-C is 
predictive regardless of TG, of some concern are studies 
that have suggested that LDL-C loses predictive value in 
people with hypertriglyceridemia and this has been found 
in multiple studies. For instance, in a cohort from the Lipid 
Research Clinics prevalence study, increasing increments of 
non-HDL-C by 30 mg/dl were associated with an increasing 
risk of cardiovascular death (Cui et al 2001) as outlined in 
Table 2. However, men with LDL-C   100 mg/dl, had an 
increased cardiovascular mortality when compared with men 
with LDL-C in the 100–130 mg/dl range. Careful analysis 
of the group of men with LDL-C   100 mg/dl showed the 
increased mortality to be conﬁ  ned to the group who also had 
TG  200 mg/dl. Similarly, an analysis of diabetics (average 
TG 254 mg/dl) also suggests a dissociation between CAD 
death and LDL-C. Diabetics with LDL-C 100–129 mg/dl had 
a lower 13-year CAD mortality than diabetics with LDL-C 
 100 mg/dl; however, the conﬁ  dence intervals were wide 
(Liu et al 2005). Given that hypertriglyceridemia affects 
16% of the American population and 37% of diabetics 
(Shepherd 2005), there is a potentially large population in 
which LDL-C does not reﬂ  ect the risk of CAD events. Indeed, 
some analyses have suggested that TG can add prognostic 
information to LDL-C but not to non-HDL-C (Pischon et al 
2005). Other studies have also compared the predictive value 
of non-HDL-C to apoB.
In 15,632 females followed in the Women’s Health study, 
non-HDL-C and apoB were the strongest lipid measures 
associated with cardiovascular end points and these two 
measures were highly correlated (r = 0.87) (see Table 2) 
(Ridker et al 2005). ApoB was not superior to non-HDL-C in Vascular Health and Risk Management 2008:4(1) 148
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Table 2   A summary of studies that have compared non-HDL-C to either LDL-C or ApoB for prediction of cardiovascular events
Population N End point  Average 
follow up 
(years)
Type of 
analysis and 
reference 
(comparator) 
group for the 
cohort 
HR (95% CI or p value) Reference
Non-HDL-C LDL-C ApoB
Men and women 
in the Fram-
ingham cohort, 
Framingham 
Offspring 
cohort, Lipid 
Research Clinics 
Prevalence Study 
and the Mul-
tiple Risk Factor 
Intervention 
Trials; 5% diabet-
ics; average BMI 
26.0; average 
TG 157 mg/dl; 
average VLDL-C 
29 mg/dl
19381; 
18363 
non-
diabetics 
and 1018 
diabetics
CAD death 13 Multivariate; 
Comparator 
for analyses is 
non-diabetics 
with LDL-C 
 100 mg/dl or 
non-diabetics 
with non-HDL-
C 130 mg/dl 
DIABETICS
Non-HDL-
C 130 mg/dl; 
2.73 (1.27–5.87)
Non-HDL-C 
130–159 mg/dl; 
2.73(1.60–4.66)
Non-HDL-C 
 160 mg/dl; 3.68 
(2.51–5.39)
NON-DIABET-
ICS
Non-HDL-C 
130–159 mg/dl; 
0.95(0.65–1.39)
Non-HDL-C 
 160 mg/dl; 2.11 
(1.52–2.91)
DIABETICS
LDL-C 
 100 mg/dl; 4.63 
(2.21–9.70)
LDL-C 100–129 
mg/dl; 2.93 
(1.53–5.61)
LDL-
C 130 mg/dl; 
5.94 (3.64–9.69)
NON-
DIABETICS
LDL-C 100–129 
mg/dl; 1.73 
(1.07–2.81)
LDL-
C 130 mg/dl; 
3.02(1.94–4.72)
NA Liu et al 
2005
Women free 
of cardiovascu-
lar disease at 
baseline enrolled 
in the Women’s 
Health Study; 3% 
diabetics; aver-
age BMI 26.3
15632 Cardiovascular 
death or non-fatal 
myocardial infarc-
tion, stroke or 
coronary revascu-
larization.
10 Multivariate; in 
each analysis, the 
ﬁ  fth quintile (Q5) 
is compared to 
the reference 
ﬁ  rst quintile 
(Q1)
Q5:Q1 
( 191 mg/dl ver-
sus  123 mg/dl); 
2.51 (1.69–3.72)
Q5:Q1 
( 154 mg/dl ver-
sus  98 mg/dl); 
1.62 (1.17–2.25)
Q5:Q1 
( 126 mg/dl ver-
sus  79 mg/dl); 
2.50 (1.68–3.72)
Ridker 
et al 2005
Men and women 
free of CAD at 
baseline; Fram-
ingham cohort; 
6.8% diabetics; 
average BMI 
24; average 
TG 111mg/dl; 
average VLDL-C 
25 mg/dl
5794 Fatal and non-fatal 
myocardial infarc-
tion, acute coronary 
insufﬁ  ciency or sud-
den cardiovascular 
death
22 Multivariate; 
Comparator 
for LDL-C 
analysis is LDL-C 
 130 mg/dl and 
for non-HDL-
C 160 mg/dl 
Non-HDL-C 
160–189 mg/dl; 
1.64 (1.13–2.40)
Non-HDL-C 
 190 mg/dl; 2.21 
(1.57–3.11)
1.008 per mg/dl 
TG   200 mg/dl 
(p   0.01)
1.006 per mg/dl 
TG 200 mg/dl 
(p   0.01)
LDL-C 130–159 
mg/dl; 1.50 
(1.05–2.15)
LDL-
C 160 mg/dl; 
2.04 (1.44–2.90)
1.009 per mg/dl 
TG   200 mg/dl
1.004 per mg/dl 
TG 200 mg/dl 
(p = NS)
NA Liu et al 
2006
Patients enrolled 
in the SHEP 
trial; age>60 
with mean 
blood pressure 
170/77 mmHg; 
10% diabetics; 
average BMI 
27.5; average TG 
144 mg/dl; 13% 
on lipid-lowering 
therapy 
4736 Non-fatal myocar-
dial infarction, CAD 
death
4.5 Multivariate; risk 
is expressed per 
40 mg/dl increase 
in lipid param-
eters
1.32 (1.13–1.54) 1.30 (1.09–1.54) NA Frost et al 
1996
(Continued)Vascular Health and Risk Management 2008:4(1) 149
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Men and women 
free of cardio-
vascular disease 
at baseline; indi-
viduals enrolled 
in the Lipid 
research clinics 
prevalence pro-
gram; 4% diabet-
ics; average BMI 
26.2; average 
TG 136 mg/dl; 
average VLDL-C 
27 mg/dl; 2% on 
lipid-lowering 
therapy
4462 Cardiovascular 
death
19 Corrected for 
age; compara-
tor for LDL-C 
analysis is LDL-C 
 130 mg/dl and 
for non-HDL-
C 160 mg/dl 
30 mg/dl incre-
ments cor-
respond to a 
19% increase in 
cardiovascular 
death in men and 
11% in women
30 mg/dl incre-
ments cor-
respond to a 
15% increase in 
cardiovascular 
death in men and 
8% in women
NA Cui et al 
2001
Chinese men 
and women free 
of cardiovascular 
disease at base-
line; 13% diabet-
ics; average BMI 
23.5; average TG 
127 mg/dl. 
3568 non-fatal myocar-
dial infarction, fatal 
CAD or coronary 
revascularization
13.6 Multivariate; in 
each analysis, the 
ﬁ  fth quintile (Q5) 
is compared to 
the reference 
ﬁ  rst quintile 
(Q1)
Q5:Q1; 1.98 
(1.00–3.92)
Q5:Q1; 1.86 
(1.00–3.46)
Q5:Q1; 2.74 
(1.45–5.19)
Chien 
et al 2007
Men and women 
free of CAD at 
baseline; Fram-
ingham cohort; 
4% diabetics. 
This Framing-
ham cohort is 
different to that 
studied by Liu 
et al (13). 
3322 myocardial 
infarction, angina 
pectoris, coronary 
insufﬁ  ciency or car-
diovascular death
15 Multivariate; 
Hazard ratios 
expressed per 
increase in one 
standard devia-
tion of the popu-
lation. Analyses 
were stratiﬁ  ed 
based on sex. 
MALE
1.22 (1.06–1.40) 
per one stan-
dard deviation 
increase
FEMALE
1.28 (1.06–1.56) 
per one stan-
dard deviation 
increase
MALE
1.11 (0.97–1.27) 
per one standard 
deviation increase
FEMALE
1.20 (0.99–1.46) 
per one standard 
deviation increase
MALE
1.37 (1.20–1.57) 
per one standard 
deviation increase
FEMALE
1.38 (1.15–1.67) 
per one standard 
deviation increase
Ingelsson 
et al 2007
1003 men and 
women with a 
CAD event and 
1885 matched 
controls 
enrolled in the 
EPIC-Norfolk 
study designed 
to study deter-
minants of can-
cer. Participants 
were apparently 
healthy and free 
of cardiovas-
cular disease 
at baseline. 3% 
diabetics; aver-
age BMI 27;  
2888 Hospital admission 
for CAD or death 
secondary to CAD.
6 years 
follow 
up; case 
control 
design
Multivariate; in 
each analysis, 
the fourth 
quartile (Q4) 
is compared to 
the reference 
ﬁ  rst quartile 
(Q1). This study 
reported odds 
ratio and not 
hazard ratios 
(HR)
Q4:Q1; 
1.63(1.26–2.11)
Q4:Q1; 1.55 
(1.22–1.96)
NA El Harcha-
oui et al 
2007
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average TG 
148 mg/dl; 0% 
using lipid-low-
ering therapy
Men and women 
with myocardial 
infarction or 
angina pectoris 
enrolled in the 
placebo arm of 
the 4S study; TG 
<220 mg/dl for 
enrolment; 
2223 CAD death or 
non-fatal myocardial 
infarction
5.4 Multivariate; 
data reported 
as relative risk 
reductions
16.4% risk reduc-
tion (p = 0.002) 
per 39 mg/dl 
decrease in non-
HDL-C
12.8% risk reduc-
tion (p = 0.024) 
per 39 mg/dl 
decrease in 
LDL-C
5.3% risk reduc-
tion (p = 0.0025) 
per 10 mg/dl 
decrease in ApoB
Pedersen 
et al 1998
Men and women 
with myocardial 
infarction or 
angina pectoris 
enrolled in the 
treatment arm 
(Simvastatin 20 
or 40 mg; aver-
age 27 mg) of 
the 4S study; TG 
<220 mg/dl for 
enrolment; 
2221 CAD death or 
non-fatal myocardial 
infarction
5.4 Multivariate; 
data reported 
as relative risk 
reductions. The 
absolute reduc-
tions in lipid 
parameters at 
one year post-
randomization 
were assessed 
for prognostic 
signiﬁ  cance over 
the study period
24.9% risk reduc-
tion (p = 0.002) 
per 39 mg/dl 
decrease in non-
HDL-C
1.7% reduction in 
events (0.9–2.4) 
per 1% reduction 
in non-HDL-C
27.8% risk reduc-
tion (p = 0.024) 
per 39 mg/dl 
decrease in 
LDL-C
1.7% reduction in 
events (1.0–2.4) 
per 1% reduction 
in LDL-C
8.8% risk reduc-
tion (p = 0.0025) 
per 10 mg/dl 
decrease in ApoB
1.1% reduction in 
events (0.3–1.8) 
per 1% reduction 
in ApoB
Pedersen 
et al 1998
Diabetics free 
of cardiovascu-
lar disease at 
baseline from 
American Indian 
Communities 
(Strong Heart 
Study); 100% dia-
betics; average 
BMI 32; average 
TG 144 mg/dl; 
2108 Cardiovascular 
death or non-fatal 
CAD, myocardial 
infarction or stroke.
9 Multivariate; 
values of LDL-C 
or non-HDL-C 
were divided 
into tertiles and 
in each analysis, 
the third tertile 
(T3) is compared 
to the reference 
ﬁ  rst tertile (T1)
T3:T1 ( 161mg/
dl versus 
 127 mg/dl); 
2.23 (1.41–3.43) 
in men; 1.80 
(1.32–2.46) in 
women
T3:T1; 1.80 
(1.27–2.54) 
TG 150 mg/dl; 
1.52 (1.12–2.07) 
TG 150 mg/dl
T3:T1 ( 115 mg/
dl versus  91mg/
dl); 1.71 
(1.17–2.48) in men; 
1.61(1.19–2.17) 
in women
T3:T1; 1.66 
(1.17–2.34) 
TG 150 mg/dl; 
1.58 (1.16–2.16) 
TG 150 mg/dl
NA Lu et al 
2003
Men of Japanese 
ancestry living 
in Oahu (The 
Honolulu Heart 
Study) free of 
CAD at baseline
1751 Fatal CAD event or 
non-fatal myocardial 
infarction
16 Multivariate; risk 
is expressed per 
20 mg/dl increase 
in lipid param-
eters; stratiﬁ  ed 
as middle aged 
(50–64 years old) 
or elderly (65–74 
years old)
MIDDLE AGE
1.18 (1.09–1.29)
ELDERLY
1.30 (1.11–1.53)
MIDDLE AGE
1.12 (1.02–1.23)
ELDERLY
1.24 (1.05–1.48)
NA Reed and 
Benfante 
1992
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Mediterra-
nean men and 
women followed 
prospectively; 
100% diabetics; 
average BMI 
27; average TG 
138 mg/dl
1565 Cardiovascular 
mortality
11 Multivariate; 
analyses strati-
ﬁ  ed based on age 
 70 and >70 
years old
comparator 
for LDL-C 
analysis is LDL-C 
 111 mg/dl and 
for non-HDL-
C 137 mg/dl 
and for ApoB 
 77 mg/dl
AGE  70
Non-HDL-C 
137–163 mg/dl; 
1.25 (0.54–2.87)
Non-HDL-C 
164–197 mg/dl; 
1.47(0.69–3.12)
Non-HDL-C 
 198 mg/dl; 1.52 
(0.72–3.23)
AGE  70
Non-HDL-C 
137–163 mg/dl; 
0.80 (0.53–1.19)
Non-HDL-C 
164–197 mg/dl; 
0.80(0.54–1.19)
Non-HDL-C 
 198 mg/dl; 0.58 
(0.36–0.93)
AGE  70
LDL-C 111–136 
mg/dl; 0.71 
(0.31–1.63)
LDL-C 
137–165 mg/dl; 
1.00(0.49–2.06)
LDL-C 
 166 mg/dl; 1.03 
(0.52–2.08)
AGE  70
LDL-C 111–136 
mg/dl; 0.96 
(0.64–1.42)
LDL-C 137–165 
mg/dl; 0.84 
(0.56–1.28)
LDL-C 
 166 mg/dl; 0.59 
(0.38–0.95)
AGE  70
ApoB 78–101 
mg/dl; 1.33 
(0.56–3.15)
ApoB 
101–126 mg/dl; 
1.94(0.84–4.49)
ApoB  127 
mg/dl; 2.86 
(1.22–6.67)
AGE  70
ApoB 78–101 
mg/dl; 1.18 
(0.73–1.91)
ApoB 
101–126 mg/dl; 
1.69(1.08–2.63)
ApoB  127 
mg/dl; 1.50 
(0.93–2.41)
Bruno 
et al 2006
Patients enrolled 
in the BARI trial; 
all had multi-
vessel CAD; 
18% diabetics; 
average TG 184 
mg/dl; 13% on 
lipid-lowering 
therapy 
1514 non-fatal myocardial 
infarction
5 Multivariate; risk 
is expressed per 
10 mg/dl increase 
in lipid param-
eters
1.049 
(1.006–1.093)
NS 1.033 
(0.981–1.088)
NA Bittner 
et al 2002
Diabetic cohort 
16% with previ-
ous myocardial 
infarction; 
100% diabetics; 
average BMI 29; 
average TG 230 
mg/dl
1059 CAD death 7 Multivariate;  1.6 (1.2–2.3); 
for non-HDL-
C  200 mg/dl 
versus  200 
mg/dl; 
NS 1.3 (0.9–1.8); 
for LDL-C 
 160 mg/dl ver-
sus  160 mg/dl
NA Lehto et al 
1997
Diabetic 
women free of 
cardiovascu-
lar disease at 
baseline enrolled 
in the Nurses’ 
Health study; 
100% diabetics; 
average BMI 
30; average TG 
200 mg/dl; 4% 
using lipid-low-
ering therapy
921 Fatal CAD event, 
non-fatal myocar-
dial infarction or 
coronary revascu-
larization
10 Multivariate; in 
each analysis, 
the fourth 
quartile (Q4) 
is compared to 
the reference 
ﬁ  rst quartile 
(Q1). Non-
HDL-C is even 
more predictive 
in those with 
TG 200 mg/dl; 
discussed in text.
Q4:Q1 (quartile 
median 224 
mg/dl versus 
126 mg/dl); 1.97 
(1.14–3.43)
Q4:Q1 (quartile 
median 179 mg/dl 
versus 98 mg/dl); 
1.93 (1.15–3.22)
Q4:Q1 (quartile 
median 131 mg/dl 
versus 74 mg/dl); 
1.78 (1.02–3.11)
Schulze 
et al 2004
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Diabetic 
men free of 
cardiovascu-
lar disease at 
baseline enrolled 
in the Health 
Professionals’ 
follow up study; 
100% diabetics; 
average BMI 
27.1; average TG 
182 mg/dl; 9% 
on lipid-lowering 
therapy
746 Fatal CAD, non-fatal 
myocardial infarc-
tion, fatal stroke, 
non-fatal stroke, 
coronary revascu-
larization
6 Multivariate; in 
each analysis, 
the fourth 
quartile (Q4) is 
compared to the 
reference ﬁ  rst 
quartile (Q1)
Q4:Q1 
( 195 mg/dl ver-
sus  143 mg/dl); 
2.25 (1.24–4.08)
Q4:Q1 
( 149 mg/dl versus 
 102 mg/dl); NS 
1.63 (0.94–2.81)
Q4:Q1 
( 119 mg/dl ver-
sus  89 mg/dl); 
2.31 (1.25–4.27)
Jiang et al 
2004
243 men with 
a CAD event 
enrolled in the 
Health Profes-
sionals’ follow 
up study and 
496 matched 
controls; 6% 
diabetics; aver-
age BMI 25.8; 
average TG 
130mg/dl; 0% on 
lipid-lowering 
therapy
739 Fatal CAD or 
non-fatal myocardial 
infarction
6 years 
follow 
up; case 
control 
design
Multivariate; in 
each analysis, the 
ﬁ  fth quintile (Q5) 
is compared to 
the reference 
ﬁ  rst quintile 
(Q1)
Q5:Q1; 2.75 
(1.62–4.67)
Q5:Q1; 2.07 
(1.24–3.45)
Q5:Q1; 2.98 
(1.76–5.06)
Pischon 
et al 2005
100 patients 
with non-fatal 
myocardial 
infarction 
before the age 
of 36 and 100 
matched con-
trols (n = 100); 
2% diabetics; 
average BMI 29; 
average TG 143 
mg/dl
200 Non-fatal myocar-
dial infarction
Case 
control
Multivariate; risk 
is expressed per 
1 mg/dl increase 
in lipid param-
eters
1.03 (1.01–1.05) 
per 1mg/dl 
increase
1.02 (1.01–1.03) 
per 1mg/dl 
increase
1.02 (1.01–1.04) 
per 1 mg/dl 
increase
Rallidis 
et al 2005
Abbreviations: BMI, body mass index; CAD, coronary artery disease; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; NS, not 
signiﬁ  cant; NA, not available; HR, hazard ratio; TG, triglycerides.
Table 2 (Continued)
Population N End point  Average 
Follow up 
(years)
Type of 
analysis and 
reference 
(comparator) 
group for the 
cohort 
HR (95% CI or p value) Reference
Non-HDL-C LDL-C ApoBVascular Health and Risk Management 2008:4(1) 153
Non-HDL cholesterol as a primary therapeutic target
predicting cardiovascular events in this primary prevention, 
female cohort. Likewise, in a diabetic male cohort (n = 746) 
with high TG (average 182 mg/dl), apoB was not superior to 
non-HDL-C in predicting cardiovascular events (Jiang et al 
2004). In contrast, other studies have suggested that apoB is a 
superior predictor of cardiovascular events than non-HDL-C 
(Pischon et al 2005, Bruno et al 2006, Chien et al 2007) and a 
stronger correlate with markers of obesity (Sattar et al 2004). 
Further, apoB may be the superior risk marker in those aged 
 70 years since there is a well described ‘reverse epidemiol-
ogy’ that occurs in elderly populations whereby high lipids 
may be protective and hypocholesterolemia may represent a 
measure of frailty or selection bias (Bruno et al 2006).
Perspective
While multiple prospective cohort studies show that 
non-HDL-C is superior to LDL-C in cardiovascular risk 
prognostication, to become the primary target of therapy 
non-HDL-C would also have to predict cardiovascular 
events in patients on statins. As shown in Table 2, the 4S 
investigators have shown non-HDL-C to predict cardio-
vascular events in patients using Simvastatin (Pedersen 
et al 1998). Also, an analysis from the Greek Atorvastatin 
and Coronary Heart Disease evaluation (GREACE) study 
showed that the relative risk reduction of cardiovascular 
events in patients prescribed Atorvastatin was highly cor-
related with percentage reductions in non-HDL-C (Athyros 
et al 2003). Further, in this study, the percentage reduction 
in hard clinical endpoints correlated more strongly with 
reductions in non-HDL-C than LDL-C (Athyros et al 2003). 
Hence, the familiar linear relationship between relative risk 
reduction in CAD death or non-fatal myocardial infarction 
and LDL-C reduction with statins (Robinson et al 2005), 
if repeated with non-HDL-C may show stronger correla-
tion and higher concordance. In this context, retrospective 
analyses of existing data and future inclusion of non-HDL-C 
as a primary outcome of lipid-lowering trials is strongly 
encouraged. The implications of such a shift in the primary 
target of therapy would probably mean intensiﬁ  cation of 
lipid lowering therapy for patients with CAD or those who 
are at high risk for CAD. For instance, in the ACCESS 
program, patients with CAD had higher non-HDL-C (and 
ApoB) relative to LDL-C and since fewer patients reached 
non-HDL-C targets than LDL-C, the use of a non-HDL-C 
could conceivably lead to the appropriate intensiﬁ  cation 
of therapy for a large number of patients (Ballantyne et al 
2001). Data from the NCEP Program Evaluation Project 
Utilizing Novel E-Technology (NEPTUNE) II Survey also 
support the notion that the adoption of non-HDL-C would 
lead to the appropriate intensiﬁ  cation of therapy in patients 
with CAD or its risk equivalents. For instance, the NEP-
TUNE II survey reported that in the cohort of CAD patients 
with TG 200 mg/dl, 57% were at the LDL-C goal of  100 
mg/dl while a mere 33% of patients achieved both LDL-C 
 100 mg/dl and non-HDL-C  130 mg/dl (Davidson et al 
2005). Hence, the adoption of non-HDL-C as the primary 
target of therapy could have multiple advantages. Firstly, it is 
easier to calculate and its routine measurement is not limited 
to patients with TG 400 mg/dl or fasting specimens (Hsia 
2003). Secondly, it is superior to LDL-C in determining car-
diovascular risk ‘across the board’. Thirdly, its superiority 
over LDL-C seems to be especially pertinent to the obese, 
which is a considerable proportion of the world. Fourthly, it 
appears that non-HDL-C predicts events in patients on statin 
therapy although this point in particular requires further 
clariﬁ  cation. Without doubt, non-HDL-C will be the lipid 
target of the future. With time, the deﬁ  nition of obesity has 
evolved from an assessment of body mass to BMI to the 
current assessment with waist circumference. Similarly, the 
primary target of lipid lowering therapy will have to evolve 
in a society that is increasingly obese.
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